 Based on this knowledge, we feel that it is justifiable to include stage II patients T2NO in combined chemoradiation studies. Our extensive experience using chemoradiotherapy in patients with regionally advanced non-metastatic Stage 4 cancers of the head and neck area suggests that selected patients with low nodal status Nondisease including those with T4 primaries i.e. T4 NO MO and T4 Nl MO have a lower risk of distant failure than patients that present with higher nodal status N2 and N3 disease. Aggressive combined locoregional therapies such as the one that will be administered in the study, are in our opinion appropriate for this group of patients as they address the major concern which is locoregional failure. 